| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.12 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Glioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients’ response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients’ response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients.
Description
Keywords
Glioblastoma Secretome Biomarkers Immunohistochemistry VEGFA YKL40 MMP-2 MMP-9
Citation
Alves, B., Peixoto, J., Macedo, S., Pinheiro, J., Carvalho, B., Soares, P., Lima, J., & Lima, R. T. (2023). High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers, 15(8), 2196. https://doi.org/10.3390/cancers15082196
Publisher
MDPI